The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Phase-change ultrasound contrast agents (PCCAs), have shown promises for ultrasound-mediated diagnostics and therapeutics. High-frame-rate ultrasound imaging with microbubbles significantly improved temporal resolution and contrast compared to conventional contrast-enhanced ultrasound imaging, offering opportunities to observe and better understand PCCA behavior after vaporisation. In this study,...
Phase-change contrast agents (PCCAs) have advantageous properties in terms of smaller size, longer half-life and selective activation control compared to conventional microbubble contrast agents (MCAs), which make them ideal for ultrasound cancer imaging. [1] Acoustic signal from tumour site can be further enhanced by receptor targeted PCCAs. However there is still a lack of understanding of the behaviour...
Targeted phase-change contrast agents (PCCAs) have shown great potential for both cancer imaging and therapy. However the acoustic response of targeted PCCAs exposed to ultrasound high frame rate imaging pulses after vaporization has not been fully explored. We herein report the investigation of the change in acoustic signal of folate receptor targeted (FR)-and non-targeted (NT)-PCCAs exposed to breast...
Contrast-enhanced high-frame-rate (HFR) ultrasound imaging offers enriched temporal information. As one of the most actively researched alternative contrast agent, the sub-micron phase-change contrast agent (PCCA) has shown attractive advantages in ultrasound imaging and therapy. Post-vaporisation of PCCAs has been optically evaluated (Reznik, 2013) and acoustically characterised (Reznik, 2011) with...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.